Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3233556 | 0.98 | NPSR1 (0.64) | NPSR1LMNAHTTL3MBTL1MAOA | |
| SCHEMBL28802227 | 0.79 | NPSR1 (1.00) | NPSR1LMNAHTTL3MBTL1MAOA | |
| SCHEMBL11208493 | 0.77 | NPSR1 (0.66) | NPSR1LMNAHTTL3MBTL1DRD2 | |
| SCHEMBL21772249 | 0.69 | L3MBTL1 (0.47) | NPSR1LMNAHTTL3MBTL1MAOA | |
| SCHEMBL866472 | 0.69 | NPSR1 (0.47) | NPSR1LMNAHTTL3MBTL1MAOA | |
| SCHEMBL7998779 | 0.69 | L3MBTL1 (0.47) | NPSR1LMNAHTTL3MBTL1ALDH1A1 | |
| SCHEMBL3238183 | 0.69 | MAOA (0.65) | NPSR1LMNAHTTL3MBTL1MAOA | |
| SCHEMBL15600621 | 0.68 | NPSR1 (0.54) | NPSR1LMNAHTTL3MBTL1MAOA | |
| SCHEMBL7937492 | 0.68 | NPSR1 (0.54) | NPSR1LMNAHTTL3MBTL1DRD2 | |
| SCHEMBL7123284 | 0.68 | NPSR1 (0.54) | NPSR1LMNAHTTL3MBTL1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745462-B2 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2010-06-29 | — | — | US | disclosed |
| CN-1798559-B | Quinoline-2-one-derivatives for the treatment of airways diseases | NOVARTIS AG | 2010-05-12 | — | — | CN | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| CN-1798559-A | Quinoline-2-one-derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2006-07-05 | — | — | CN | disclosed |
| EP-1613315-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087142-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | NPSR1 150/4885LMNA 1195/4885HTT 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.